Navigation Links
NORTHWEST BIO Announces Positive Third Quarter Progress
Date:10/6/2011

review by the Company, as well as through other distribution channels.

Linda Powers, CEO of NORTHWEST BIO, commented that "It is gratifying to see that the expanded management team put in place in June is moving the GBM clinical trial forward at an accelerating rate, while taking important steps toward strengthening our investor and media outreach."  

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis in both the US and Europe.  The Company has a broad platform technology for dendritic cell-based vaccines.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, ther
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
2. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
3. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
4. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
5. Northwest Biotherapeutics Announces Change and Expansion of Management Team
6. Northwest Biotherapeutics Announces Series of Financing Arrangements
7. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
8. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
9. Northwest Biotherapeutics Addresses Recent Market Activity
10. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
11. Registration Open for WBBAs Life Science Innovation Northwest 2011 Event Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 “2014 Deep ... Industry” is a professional and in-depth research ... The report introduces Lubricant basic information, including ... structure and industry overview. This research covers ... market as well as global industry analysis ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Proove ... medicine, will be exhibiting data and research conducted through ... International Spine Intervention Society’s (ISIS) 22nd Annual Scientific ... at the Hyatt Regency, in Orlando, Florida. ... and clinical competence of physicians who care for patients ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire/ -   JOLT ... group of companies to join its growing portfolio of ... of Toronto,s JOLT accelerator, and ... on the roster. Since its launch ... have successfully raised  $7.5M of financing. Now at 23 ...
(Date:7/28/2014)... YORK , July 28, 2014  David ... ConvergeHEALTH by Deloitte , has been elected ... Interchange Standards Consortium, a non-profit working to establish ... data, particularly as it relates to electronic health ... continue CDISC,s mission of collaborating with organizations across ...
Breaking Biology Technology:Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... today that revenue for the three months,ended September 30, ... three months ended September 30, 2007. The decline in ... primarily driven by a $2.8,million reduction in private label ...
... SHANGHAI, China, Nov. 7 /Xinhua-PRNewswire/ -- WuXi ... medical device research,and development outsourcing company with ... today that it has signed a new ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ...
... are developing technologies that will fuel the continued growth ... financial boost through the 2008 Clean Tech Innovation Challenge. ... partnership between the City of San Diego, UC San ... San Diego State University (SDSU). The program is designed ...
Cached Biology Technology:Osteotech Reports 2008 Third Quarter Financial Results 2Osteotech Reports 2008 Third Quarter Financial Results 3Osteotech Reports 2008 Third Quarter Financial Results 4Osteotech Reports 2008 Third Quarter Financial Results 5WuXi PharmaTech Signs New Collaboration Agreement With Pfizer 2San Diego universities, government and industry rally around local Clean-Tech cluster 2San Diego universities, government and industry rally around local Clean-Tech cluster 3San Diego universities, government and industry rally around local Clean-Tech cluster 4San Diego universities, government and industry rally around local Clean-Tech cluster 5
(Date:7/28/2014)... led by the University of Arizona has sequenced the ... will enhance scientists, and agriculturalists, understanding of the growing ... development of new rice varieties that are better able ... global hunger challenges. , The paper, "The genome sequence ... for independent domestication," was published online in Nature ...
(Date:7/28/2014)... juvenile rat brain cells suggests that the effects of ... brain cells are temporary. , The study, published in ... , was conducted by biologists at the University of ... New York in response to concerns, arising from multiple ... children to general anesthetics may increase their susceptibility to ...
(Date:7/28/2014)... New research has identified areas of the Earth that ... climate change. , Europe is particularly vulnerable, as it ... four per cent, of any continent in ,refugia, ... natural environmental conditions remain relatively constant during times of ... Europe are mostly in Scandinavia and Scotland. , ...
Breaking Biology News(10 mins):Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2
... (DIYbio) community has grown, so have concerns among media ... DNA and manipulate life. In 2009, for example, ... the popular misconception: "In Attics and Closets, ,Biohackers, Discover ... survey of DIYbio practitioners (DIYers), the Synthetic Biology Project ...
... years ago, mammalian target of rapamycin or mTOR, a ... the antidepressant effects of ketamine, the first rapidly acting ... later, a group at the National Institutes of Mental ... receptor antagonist, also produced rapidly appearing antidepressant effects, similar ...
... APOPKA, FL--Shade nets are widely used in ornamental crop ... and birds. According to a 2011 study from the ... production in the United States occurred under shade or ... growers have begun experimenting with colored, gray, and white ...
Cached Biology News:First-ever survey of Do-It-Yourself Biology community challenges myths 2mTOR: A key brain signaling mechanism for rapidly acting antidepressants 2Shadehouses with photoselective nets featured in study of growing conditions 2
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
... 100%,S-Adenosyl Methionine 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... Assay Range: 0.1 ug/ml to 1 mg/ml,(0.26 M to 2.6 mM) ...
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: